Literature DB >> 233679

"Normal suppression" to dexamethasone in Cushing's disease: an expression of decreased metabolic clearance for dexamethasone.

J F Caro, A W Meikle, J H Check, S N Cohen.   

Abstract

The adrenal cortical function of a patient with pituitary-dependent Cushing's syndrome exhibited normal responsiveness to conventional doses of dexamethasone (Dex) over several years of evaluation. "Periodic hormonogenesis" did not seem to explain the phenomenon. Plasma concentrations of Dex were measured to ascertain whether an abnormality in Dex metabolism might explain the apparent discrepancy in Dex responsiveness. Plasma levels of Dex after oral administration of the steroid were higher than normal, suggesting that decreased clearance of Dex accounts for the phenomenon of "normal suppression" in this patient with Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 233679     DOI: 10.1210/jcem-47-3-667

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Influence of the time of administration of dexamethasone 0.25 mg on cortisol secretion in normal humans.

Authors:  P Schulz; C Costa; J Widmer; P Dick
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology.

Authors:  J A Yanovski; G B Cutler; G P Chrousos; L K Nieman
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

3.  Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism.

Authors:  B Ambrosi; D Bochicchio; R Ferrario; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

4.  Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test.

Authors:  Bjørn O Asvold; Valdemar Grill; Ketil Thorstensen; Marit R Bjørgaas
Journal:  Endocr Connect       Date:  2012-08-30       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.